| abstract |
Use of a compound of general formula (I), wherein R1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C¿1-6?alkyl, C1-6alkoxy, arylC1-6alkoxy, -CO2R?4¿, -(CH¿2?)nCN, -(CH2)nCONR?5R6¿, -(CH¿2?)nSO2NR?5R6, C¿1-6alkanolyamino(CH2)n, or C1-6alkylsulphonylamino(CH2)n; R4 represents hydrogen, C¿1-6?alkyl or arylC1-6alkyl; R?5 and R6¿ each independently represent hydrogen or C¿1-6¿alkyl, or R?5 and R6¿ together with the nitrogen atom to which they are attached form a ring; n represents 0, 1 or 2; and R?2 and R3¿ each independently represent hydrogen, C¿1-6?alkyl or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring; or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT1-like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described. |